| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Cerus Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.02 |
| 52 Week High | US$2.59 |
| 52 Week Low | US$1.21 |
| Beta | 1.19 |
| 11 Month Change | -7.34% |
| 3 Month Change | 13.48% |
| 1 Year Change | 23.17% |
| 33 Year Change | -67.47% |
| 5 Year Change | -62.03% |
| Change since IPO | -83.34% |
Recent News & Updates
Analysts Are Upgrading Cerus Corporation (NASDAQ:CERS) After Its Latest Results
Aug 04
Cerus Corporation's (NASDAQ:CERS) 30% Jump Shows Its Popularity With Investors
Jul 18Does Cerus (NASDAQ:CERS) Have A Healthy Balance Sheet?
Jul 12Recent updates
Analysts Are Upgrading Cerus Corporation (NASDAQ:CERS) After Its Latest Results
Aug 04Cerus Corporation's (NASDAQ:CERS) 30% Jump Shows Its Popularity With Investors
Jul 18Does Cerus (NASDAQ:CERS) Have A Healthy Balance Sheet?
Jul 12The Cerus Corporation (NASDAQ:CERS) First-Quarter Results Are Out And Analysts Have Published New Forecasts
May 05Here's Why Cerus (NASDAQ:CERS) Can Afford Some Debt
Apr 12Cerus Corporation (NASDAQ:CERS) Stock Rockets 29% But Many Are Still Ignoring The Company
Mar 07Slammed 29% Cerus Corporation (NASDAQ:CERS) Screens Well Here But There Might Be A Catch
Jan 18Health Check: How Prudently Does Cerus (NASDAQ:CERS) Use Debt?
Oct 06Is Cerus (NASDAQ:CERS) A Risky Investment?
Jul 07Slammed 32% Cerus Corporation (NASDAQ:CERS) Screens Well Here But There Might Be A Catch
May 12Cerus: Technical Support Fades, Investment Case Weakens (Technical Analysis)
Sep 29Cerus GAAP EPS of -$0.05 beats by $0.02, revenue of $47.63M beats by $4.87M
Aug 04Cerus: Lacks Conviction Against Macro Backdrop, Technicals Supportive Of Near-Term Upside
Jul 14Is Cerus (NASDAQ:CERS) Using Debt In A Risky Way?
Jul 06Is Cerus (NASDAQ:CERS) Using Debt Sensibly?
Mar 17Cerus Corporation: Outperforming And Gaining Momentum
Jan 28Shareholder Returns
| CERS | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -10.6% | -1.4% | -4.4% |
| 1Y | 23.2% | 14.0% | 19.1% |
Return vs Industry: CERS exceeded the US Medical Equipment industry which returned 14% over the past year.
Return vs Market: CERS exceeded the US Market which returned 21.3% over the past year.
Price Volatility
| CERS volatility | |
|---|---|
| CERS Average Weekly Movement | 11.2% |
| Medical Equipment Industry Average Movement | 8.6% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CERS has not had significant price volatility in the past 3 months.
Volatility Over Time: CERS's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1991 | 631 | Obi Greenman | www.cerus.com |
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
Cerus Corporation Fundamentals Summary
| CERS fundamental statistics | |
|---|---|
| Market cap | US$374.30m |
| Earnings (TTM) | -US$24.06m |
| Revenue (TTM) | US$169.98m |
2.2x
P/S Ratio-15.6x
P/E RatioIs CERS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CERS income statement (TTM) | |
|---|---|
| Revenue | US$169.98m |
| Cost of Revenue | US$76.27m |
| Gross Profit | US$93.71m |
| Other Expenses | US$117.77m |
| Earnings | -US$24.06m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.13 |
| Gross Margin | 55.13% |
| Net Profit Margin | -14.15% |
| Debt/Equity Ratio | 166.2% |
How did CERS perform over the long term?
See historical performance and comparison